mitoxantrone has been researched along with Anemia in 11 studies
Mitoxantrone: An anthracenedione-derived antineoplastic agent.
mitoxantrone : A dihydroxyanthraquinone that is 1,4-dihydroxy-9,10-anthraquinone which is substituted by 6-hydroxy-1,4-diazahexyl groups at positions 5 and 8.
Anemia: A reduction in the number of circulating ERYTHROCYTES or in the quantity of HEMOGLOBIN.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Grade 3/4 neutropenia was observed in 29 patients (58%) with four neutropenic episodes." | 6.69 | First-line treatment of metastatic breast cancer with mitoxantrone, vinorelbine, and carboplatin. ( Agelaki, S; Androulakis, N; Georgoulias, V; Hatzidaki, D; Kakolyris, S; Koukourakis, M; Kourousis, C; Samonis, G; Tsiftsis, D; Vamvakas, L, 1999) |
| "For previously treated advanced breast cancer, there is no standard second-line therapy." | 5.30 | Treatment of previously treated metastatic breast cancer by mitoxantrone and 48-hour continuous infusion of high-dose 5-FU and leucovorin (MFL): low palliative benefit and high treatment-related toxicity. ( Chen, PM; Chiou, TJ; Hsieh, RK; Liu, JH; Tung, SL; Wang, WS; Yen, CC, 1997) |
| "A comparison of patients receiving combination chemotherapy with mitomycin C, mitozantrone and methotrexate (3M) with and without tamoxifen for treatment of primary breast cancer indicates an increased risk of anaemia (P < 0." | 5.07 | A toxic interaction between mitomycin C and tamoxifen causing the haemolytic uraemic syndrome. ( Ashley, SE; Luckit, J; Montes, A; O'Brien, ME; Powles, TJ; Treleaven, J, 1993) |
| "Mitoxantrone is used for aggressive multiple sclerosis (MS), but concerns about safety, including cardiotoxicity and other laboratory measures, prevail." | 3.76 | Cardiotoxicity and other adverse events associated with mitoxantrone treatment for MS. ( Geddes, J; Isserow, S; Kingwell, E; Koch, M; Leung, B; Rieckmann, P; Tremlett, H, 2010) |
| "Grade 3/4 neutropenia was observed in 29 patients (58%) with four neutropenic episodes." | 2.69 | First-line treatment of metastatic breast cancer with mitoxantrone, vinorelbine, and carboplatin. ( Agelaki, S; Androulakis, N; Georgoulias, V; Hatzidaki, D; Kakolyris, S; Koukourakis, M; Kourousis, C; Samonis, G; Tsiftsis, D; Vamvakas, L, 1999) |
| "For previously treated advanced breast cancer, there is no standard second-line therapy." | 1.30 | Treatment of previously treated metastatic breast cancer by mitoxantrone and 48-hour continuous infusion of high-dose 5-FU and leucovorin (MFL): low palliative benefit and high treatment-related toxicity. ( Chen, PM; Chiou, TJ; Hsieh, RK; Liu, JH; Tung, SL; Wang, WS; Yen, CC, 1997) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 5 (45.45) | 18.2507 |
| 2000's | 4 (36.36) | 29.6817 |
| 2010's | 2 (18.18) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Kaneko, H | 1 |
| Katoh, T | 1 |
| Hirano, I | 1 |
| Hasegawa, A | 1 |
| Tsujita, T | 1 |
| Yamamoto, M | 1 |
| Shimizu, R | 1 |
| Kingwell, E | 1 |
| Koch, M | 1 |
| Leung, B | 1 |
| Isserow, S | 1 |
| Geddes, J | 1 |
| Rieckmann, P | 1 |
| Tremlett, H | 1 |
| Sheen, WC | 1 |
| Chen, JS | 1 |
| Wang, HM | 1 |
| Yang, TS | 1 |
| Liaw, CC | 1 |
| Lin, YC | 1 |
| Errante, D | 1 |
| Bianco, A | 1 |
| Aversa, SML | 1 |
| Salvagno, L | 1 |
| Barista, I | 1 |
| Tekuzman, G | 1 |
| Firat, D | 1 |
| Baltali, E | 1 |
| Kansu, E | 1 |
| Kars, A | 1 |
| Ozisik, Y | 1 |
| Ruacan, S | 1 |
| Uzunalimoğlu, B | 1 |
| Karaağaoğlu, E | 1 |
| Damon, LE | 1 |
| Rugo, HS | 1 |
| Ries, CA | 1 |
| Linker, CA | 1 |
| Montes, A | 1 |
| Powles, TJ | 1 |
| O'Brien, ME | 1 |
| Ashley, SE | 1 |
| Luckit, J | 1 |
| Treleaven, J | 1 |
| Yen, CC | 1 |
| Tung, SL | 1 |
| Hsieh, RK | 1 |
| Chiou, TJ | 1 |
| Liu, JH | 1 |
| Wang, WS | 1 |
| Chen, PM | 1 |
| Kakolyris, S | 1 |
| Kourousis, C | 1 |
| Koukourakis, M | 1 |
| Androulakis, N | 1 |
| Vamvakas, L | 1 |
| Agelaki, S | 1 |
| Hatzidaki, D | 1 |
| Samonis, G | 1 |
| Tsiftsis, D | 1 |
| Georgoulias, V | 1 |
| Thurnher, D | 1 |
| Kornfehl, J | 1 |
| Burian, M | 1 |
| Gedlicka, C | 1 |
| Selzer, E | 1 |
| Quint, C | 1 |
| Neuchrist, C | 1 |
| Kornek, GV | 1 |
| Siemens, HJ | 1 |
| Gerke, P | 1 |
| Steinhoff, J | 1 |
| Roth-Isigkeit, A | 1 |
| Wagner, K | 1 |
| Brückner, S | 1 |
3 trials available for mitoxantrone and Anemia
| Article | Year |
|---|---|
A toxic interaction between mitomycin C and tamoxifen causing the haemolytic uraemic syndrome.
Topics: Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Drug Interact | 1993 |
First-line treatment of metastatic breast cancer with mitoxantrone, vinorelbine, and carboplatin.
Topics: Adult; Aged; Alopecia; Anemia; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplas | 1999 |
Ifosfamide and mitoxantrone in the treatment of recurrent and/or metastatic squamous cell carcinoma of the head and neck.
Topics: Adult; Aged; Anemia; Antigens, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, | 2001 |
8 other studies available for mitoxantrone and Anemia
| Article | Year |
|---|---|
Induction of erythropoietin gene expression in epithelial cells by chemicals identified in GATA inhibitor screenings.
Topics: Anemia; Animals; Base Sequence; Cells, Cultured; CRISPR-Cas Systems; Epithelial Cells; Erythropoieti | 2017 |
Cardiotoxicity and other adverse events associated with mitoxantrone treatment for MS.
Topics: Adult; Age Factors; Analgesics; Anemia; Female; Follow-Up Studies; Humans; Liver Diseases; Male; Mid | 2010 |
A modified low-dose regimen of mitoxantrone and prednisolone in patients with androgen-independent prostate cancer.
Topics: Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Disease Progression; Drug Administrati | 2004 |
Comment on: 'Non-Hodgkin's lymphoma in very elderly patients over 80 years. A descriptive analysis of clinical presentation and outcome'.
Topics: Administration, Oral; Aged, 80 and over; Anemia; Antineoplastic Combined Chemotherapy Protocols; Ble | 2008 |
Non-Hodgkin's lymphomas in Turkey: eighteen years' experience at the Hacettepe University.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Analysis of Variance; Anemia; Antineoplastic Agents; Ant | 1994 |
Post-remission cytopenias following intense induction chemotherapy for acute myeloid leukemia.
Topics: Acute Disease; Adolescent; Adult; Anemia; Antineoplastic Combined Chemotherapy Protocols; Bone Marro | 1994 |
Treatment of previously treated metastatic breast cancer by mitoxantrone and 48-hour continuous infusion of high-dose 5-FU and leucovorin (MFL): low palliative benefit and high treatment-related toxicity.
Topics: Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasm | 1997 |
A prolonged APTT in a patient with a low grade malignant NHL - a case report.
Topics: Anemia; Antineoplastic Combined Chemotherapy Protocols; Autoantibodies; Blood Coagulation Factors; C | 2002 |